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Abstract 
 
Schistosoma haematobium is a parasitic flatworm that infects millions of people, mostly in the 
developing world, and is associated with high incidence of bladder cancer, although why is not 
clear. Previously, we have used CD-1 mice to show that Schistosoma haematobium total antigen 
(Sh) has a carcinogenic ability. Sh intravesically instillation induced the development of several 
urothelial lesions, namely nodular hyperplasia and dysplasia (LGIUN—Low Grade Intra-
Urothelial Neoplasia) after 40 weeks of treatment. These results suggested that Sh induce 
urothelium malignization. Bladder carcinoma frequently harbours gene mutations that 
constitutively activate the receptor tyrosine kinase-Ras pathway for this reason we studied 
activating mutations in KRAS gene. Twenty percent of the bladders with dysplasia presented a 
KRAS mutation in codon 12 of exon 2. We concluded from these results that the parasite extract 
of S. haematobium has carcinogenic ability possibly through oncogenic mutation of KRAS gene. 
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Introduction 
 
Schistosomiasis is a common parasitic 
disease that ranks second only to malaria as 
a global cause of morbidity and mortality. It 
occurs in 76 tropical and subtropical 
countries and affects about 10% of the 
world’s population. The prevalence of this 
infection remains high despite the 
availability of efficacious antischistosomal 
drugs. Individuals become infected with the 
parasite at an early age by exposure to the 
free-swimming larval stage (termed 
cercariae) in contaminated water (Rosin et 
al, 1994). Schistosomiasis is the first in 
prevalence among all water-borne 
infectious diseases and one of the main 
occupational risks encountered in the rural 
endemic areas of the world. 
Schistosomiasis-associated bladder cancer 
defines a characteristic pathological and 
histogenic nature that differentiates it from 
bladder cancer of non-schistosomal origin. 
It shows an increased incidence of 
squamous cell carcinoma as opposed to 
transitional cell carcinoma, a lower mean 
age at diagnosis, and a higher male/female 
ratio. Moreover, in association with 
schistosomiasis, cancer may originate 
throughout the bladder but rarely in the 
trigone, a frequent site of tumor origin in 
non-schistosomal cases (Badawi, 1996). 
Human bladder cancer is the fifth to the 
seventh most common cancer in Western 
countries. In many tropical and subtropical 
areas, however, it is the first among all types 
of cancer, mainly due to the endemic 
parasitism (Badawi, 1996). 
 
Many oncogenes participate in the 
development of human tumors. The most 
frequently activated genes are members of 
the RAS gene family, two of which (Harvey- 
H) and (Kirsten-K) were first identified as 
being homologous to viral transforming 
genes, while the third (N-ras) was identified 
in a human neuroblastoma. The RAS gene 
product is a monomeric membrane-
localized G protein of 21 Kd that functions 
as a molecular switch linking receptor and 
nonreceptor tyrosine kinase activation to 
downstream cytoplasmic or nuclear events. 
Each mammalian cell contains at least 3 
distinct RAS proto-oncogenes encoding 
closely related, but distinct proteins. RAS 
genes can be activated by point mutation at 
codons 12, 13, 61, or 113-117. Signal 
transduction by Ras proteins involves 
hydrolysis of GTP, and activating mutations 
inhibit this process, locking the protein in 
the “on” signaling conformation (Stanley, 
1995). 
 
Activating mutations in these Ras proteins 
result in constitutive signaling, thereby 
stimulating cell proliferation and inhibiting 
apoptosis. Oncogenic mutations in the RAS 
genes are present in approximately 30% of 
all human cancers (Adjei, 2001). The high 
degree of similarities shared by different 
Ras isoforms suggests that functional 
redundancy exists among these proteins, yet 
accumulating data support for unique roles 
of the Ras family members with K-ras being 
the most important Ras isoform (Zhang et 
al, 2007). Oncogenic KRAS mutations are 
prevalent in virtually all cancer types, 
making KRAS one of the most frequently 
mutated genes in human cancers (Zhang et 
al, 2007).  
 
Mutational activation of RAS 
protooncogenes is frequently observed in 
human tumors and in experimental animals 
(Cerutti P et al, 1994). KRAS mutations have 
been found in bladder cancer patients (Jebar 
et al, 2005; Gormally et al, 2006), in 
transformed bladder epithelial cells 
(Brookes et al, 1988) and chemically-
induced rat bladder tumors (Stanley, 1995). 
 
We have previously demonstrated that 
normal CHO (Chinese Hamster Ovary) cells 
treated in laboratory with S. haematobium 
total antigen, acquire cancer-like 
characteristics. In fact, these cells presented 
rapid uncontrolled division, high resistance 
to death and an abnormal capability to 
migrate (Botelho et al, 2009a) and, when 
injected into nude mice, lead to tumour 
development. Crucially, animals injected 
with non-exposed cells showed no growth 
(Botelho et al, 2009b). We have further used 
CD-1 mice to show that Schistosoma 
haematobium total antigen (Sh) has a 
carcinogenic ability. Sh intravesically 
instillation induced the development of 
dysplasia in 70% of animals sacrificed 40 
weeks after. Our results suggest that Sh 
induce the malignization of the urothelium 
(Botelho et al, 2011). Dysplasia (LGIUN— 
Low Grade Intra-Urothelial Neoplasia) is 
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preneoplastic lesion that can evolutes to 
carcinoma in situ, invasive carcinoma 
and/or papillary carcinoma. In the present 
study, we addressed gene mutations that 
constitutively activate the receptor tyrosine 
kinase-Ras pathway and therefore we 
studied activating mutations in KRAS gene. 
Twenty percent of the bladders with 
dysplasia presented a KRAS mutation in 
codon 12 of exon 2. We concluded from 
these results that the parasite extract of S. 
haematobium may have carcinogenic ability 
possibly through oncogenic mutation of 
KRAS gene. 
 
An improved understanding of the 
molecular basis underlying bladder tumor 
pathways and specifically schistosomiasis-
associated bladder cancer is of clear 
importance in helping to better predict 
bladder tumor progression and devise 
optimal management strategies for this type 
of carcinoma. 
 
Material and Methods 
 
Animals 
 
Eight-week-old female golden hamsters 
(LVG/SYR) and CD-1 mice were provided by 
Charles River (Barcelona, Spain). Animals 
spent one week being acclimated under 
routine laboratory conditions before 
starting the experiments. They did not 
receive any treatment prior to the study. 
Hamsters were kept in separated cages and 
mice were kept in 6 litter mates cage. They 
were fed standard balanced food and water 
ad libitum. All the animals were maintained 
at the National Institute of Health (Porto, 
Portugal) in rooms with controlled 
temperature (22 ± 2ºC) and humidity (55% 
± 10%) and continuous air renovation. 
Animals were housed in a 12 h light/12 h 
dark cycle (8 am-8 pm). All animal 
experiments were performed in accordance 
with the National (DL 129/92; DL 197/96; P 
1131/97) and European Convention for the 
Protection of Animals used for Experimental 
and Other Scientific Purposes and related 
European Legislation (OJ L 222, 24.8.1999). 
 
Experimental Infections 
 
Urine was collected from S. haematobium-
infected individuals. The individuals were 
living in Angola, an endemic area for 
schistosomiasis. Informed consent from 
patients was obtained. S. haematobium 
infection was detected by microscopically 
observation of the eggs in the sediment of 
centrifuged urine. The eggs were hatched 
and with the resulting miracidia, snails from 
susceptible species were infected. 
 
Golden hamsters were experimentally 
infected with 100 cercariae by tail 
immersion. The control animals consisted of 
littermates. The cercariae were obtained by 
shedding of snails infected with miracidia. 
 
S. Haematobium Total Antigen (Sh) 
Production  
 
Angolan strain of S. haematobium adult 
worms were collected by perfusion of the 
hepatic portal system of golden hamsters at 
seven weeks after infection with 100 
cercarie. The worms were suspended in PBS 
and then sonicated. The protein extract was 
then ultracentrifuged and the protein 
concentration was estimated using a micro 
BCA protein assay reagent kit. 
 
Experimental Design 
 
Forty mice were randomly divided into six 
experimental groups. Groups 1 and 3 (n=10) 
were Sh-instilled animals. Groups 2 (n=5) 
and 4 (n=5) were control animals with their 
bladders instilled with saline only. Groups 1 
and 2 were sacrificed 20 weeks after 
instillation; group 3 and 4 were sacrificed 
40 weeks after instillation. For the duration 
of the study, the mice’s state of health was 
monitored daily.  
 
For intravesical instillation of the parasite 
total antigen, 50 g/ml of Sh was 
introduced directly into the urinary 
bladders of female mice via the urethra 
according to the procedure previously 
described (Chin et al, 1996). Briefly, animals 
were anesthetized with an intraperitoneal 
injection of sodium pentobarbital (40 
mg/kg). The bladder was catheterized via 
the urethra with a 24 gauge plastic 
intravenous cannula and the bladder 
mucosa was then traumatized to remove the 
umbrella cells of the urothelium by instilling 
0.1 ml of 0.1N HCl solution for 15 seconds, 
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neutralized with 0.1 ml of 0.1N KOH and 
flushed with sterile saline. 
 
A total of 150 l of Sh with a concentration 
of 50 g/ml was instilled via the cannula. 
The dwell time after instillation was 
approximately 1 hour. The mice were 
turned 90 degrees every 15 minutes to 
facilitate whole bladder exposure to the Sh 
intravesically instilled. One hour after the 
instillation, micturition of the mice was 
induced by light abdominal massage so that 
the duration of exposure was constant. Body 
temperature was maintained with a 
homoeothermic bandage. All the 
experiments described herein were carried 
out under aseptic conditions and performed 
once during this study. 
 
All animals were sacrificed by 
intraperitoneal administration of sodium 
pentobarbital (130 mg/Kg). Complete 
necropsies were carefully conducted. All 
organs were examined macroscopically for 
any changes. The urinary bladders were 
inflated in situ by injection of 10% 
phosphate buffered formalin (150μl), 
ligated around the neck to maintain proper 
distension and then were immersed in the 
same solution for 12 hours. After fixation, 
the formalin was removed; the urinary 
bladder was cut into two strips, and 
routinely processed. Tissue sections (2 μm) 
from urinary bladder, spleen, liver and lung 
were stained with haematoxylin and eosin 
(HE) to characterize changes and 
inflammatory infiltrate. 
 
Mutation Analysis of KRAS Gene 
 
Whole tissue of the bladders was used for 
mutational analysis of KRAS codon 12. 
Direct sequencing was performed and Big 
Dye Terminator (version 1.1) was used 
according to instructions of supplier 
(Applied Biosystems). 
Results 
 
Animals’ General Aspect 
 
During the experimental work no animal 
died and all, animals exhibited normal cage 
activity. The weight of the animals remained 
normal throughout the experiment (data 
not shown). 
 
Macroscopic and Microscopic Evaluation 
 
The bladders from all groups showed no 
gross lesions. No macroscopic changes were 
seen in the liver, lungs or kidneys of all 
animals. The mean liver, kidney and bladder 
weights, as well as relative liver, kidney and 
bladder weights at the end of the study did 
not show differences (data not shown). 
 
The bladder histopathological findings 
observed in all groups are given in Table 1 
and Figure 1. Bladder histopathology of 
animals instilled with Sh was characterized 
by extensive diffuse or nodular infiltrate 
composed predominantly of lymphocytes 
admixed with variable number of 
eosinophils, and by absence of umbrella 
cells, nodular hyperplasia and dysplasia. 
The nodular hyperplasia exhibiting budlike 
proliferated urothelial cells extending into 
the lamina propria. After 20 weeks of 
treatment 30% of these animals displayed 
urothelial dysplasia a LGIUN (Low Grade 
Intra Urothelial Neoplasia), whereas after 
40 weeks of treatment we found 70% of the 
bladders with this LGIUN, a non-invasive 
malignant flat lesion in the urothelium of 
these animals. Mastocytes were only found 
in the bladders of animals sacrificed after 40 
weeks. No bladder histopathological 
changes were observed in animals from 
control groups. No microscopic changes 
were seen in the spleen, lung, kidney and 
liver in samples obtained from all animals. 
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Table 1: Histopathological Findings in the Sh Instilled Bladders and Controls 
 
Group n W N U I L M D 
Group 1 
(Sh treated) 
10 20 7/10 
(70%) 
5/10 
(50%) 
9/10 
(90%) 
9/10 
(90%) 
0/10 
(0%) 
3/10 
(30%) 
Group 2 
(Control) 
10 20 10/10 
(100%) 
9/10 
(90%) 
2/10 
(20%) 
2/10 
(20%) 
0/10 
(0%) 
0/10 
(0%) 
Group 3 
(Sh treated) 
10 40 0/10 
(0%) 
0/10 
(0%) 
10/10 
(100%) 
9/10 
(90%) 
4/10 
(40%) 
7/10a 
(70%) 
Group 4 
(Control) 
10 40 10/10 
(100%) 
10/10 
(100%) 
3/10 
(30%) 
3/10 
(30%) 
0/10 
(0%) 
0/10 
(0%) 
n, number of animals; W, weeks between treatment and sacrifice; N, normal urothelium; U, presence of umbrella cells; I, 
inflammatory infiltrate; L, infiltration of lymphocyte; M, infiltration of mastocytes; D, dysplasia. a (p=0.001, Group 3 Vs. 
Group 4) (12). 
 
 
Figure 1: (A and B) Control, (C) Urothelium Displaying an Inflammatory Nodule and a 
Lesion with Characteristics of Nodular Hyperplasia, (D) Denudation and Dysplasia, (E) 
Inflammatory Infiltrate and Dysplasia, (F) Inflammatory Nodule and Dysplasia (12) 
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Frequency of KRAS Mutations in Codon 
12 
 
Two (out of 10) of the bladders with 
dysplasia presented a KRAS mutation in 
codon 12 of exon 2 (Fig. 2). This results in 
Gly12Asp mutation. The controls showed no 
mutation. We concluded from these results 
that the parasite extract of S. haematobium 
has carcinogenic ability possibly through 
oncogenic mutation of KRAS gene. 
 
 
Figure 2: KRAS Exon 2 Sequencing Results. (A) Control, (B) Dysplastic Bladder with a 
Mutation at Codon 12 (Resulting in a Gly12Asp Mutation). 
 
Discussion 
 
Bladder cancer is a complex disease, with a 
multitude of genetic aberrations already 
uncovered, and likely more still to come. We 
previously demonstrated that Schistosoma 
haematobium total antigen has a 
carcinogenic ability in a CD-1 mice model. 
We showed that intravesically 
administration of Sh gave rise to a high 
incidence of urothelial dysplasia, a non-
invasive malignant flat lesion, in 70% of the 
tested subjects after 40 weeks of treatment. 
In the present study, we were able to 
investigate this effect further and show that 
20% of the dysplastic bladders presented a 
mutation in codon 12 of KRAS gene. 
 
It is generally recognized that the 
pathogenesis of malignancy involves three 
distinct and sequential effects on the target 
cells; initiation, promotion and progression. 
The first stage is thought to involve the 
formation of damage in the DNA resulting in 
a somatic cell mutation. The essential 
feature of promotion, however, is the 
induction of proliferation in the initiated 
cells by agents that are not necessarily 
carcinogenic per se (Gutiérrez and 
Salsamendi, 2001). The sequence of lesions 
identified, via histopathology, between 
initiation and promotion are designated as 
preneoplastic lesions and/or benign 
neoplasias (Gutiérrez and Salsamendi, 
2001). Their transformation into malignant 
lesions is the last of the stages of 
carcinogenesis and is the most extended – it 
is labelled progression (Klaunig et al, 2000; 
Williams, 2001). We cannot state at this 
point that KRAS mutation that we detected 
in dysplastic bladders induced by Sh 
treatment is an initiating event. The 
presence of this mutation could have one of 
two explanations: either the parasite total 
antigen has carcinogenic molecule(s) 
sufficiently genotoxic and, consistent with 
the mutation observed, caused direct attack 
on the RAS gene leading to uncontrolled 
proliferation of the cells and causing 
dysplasia in the bladders treated with the 
parasite antigen; or the parasite antigens 
are only mitogenic for the urothelial cells 
causing increased proliferation that resulted 
in the KRAS mutation via non-carcinogen-
mediated pathways. 
 
In agreement with the first explanation 
other researchers have well characterized 
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the phenomenon of RAS oncogene activation 
in a number of systems. In some cases, such 
as the mouse and rat mammary gland, RAS 
activation is clearly an important initiating 
event, and when tumors are induced by 
genotoxic carcinogens the mutations 
observed are consistent with direct attack 
by the carcinogen on the RAS gene (Stanley, 
1995). Also the majority of evidence taken 
from several animal studies suggests that 
RAS proto-oncogene activation is an early 
event. This presumption is derived from 
detection of RAS activation in benign (early) 
tumors of skin, lung and liver. Based upon 
tumor induction following a brief exposure 
to carcinogens that produce a chemical-
specific point mutation in RAS activation, 
researchers have suggested that activation 
of RAS may be the initiating event in some 
model systems (Moronpot et al, 1995). 
Furthermore, the activated RAS gene has 
been detected in many benign tumors, 
including mouse skin papillomas, mouse 
lung and liver adenomas, and basal cell and 
clitoral gland tumors of the rat. This implies 
that the activated RAS was present in the 
cell that clonally expanded to these benign 
tumors. Thus, activation of the RAS proto-
oncogene may be the initiation event in 
some model systems (Stowers et al, 1987). 
 
Few studies were carried out to investigate 
the role and frequency of activated RAS in 
schistosomiasis-associated bladder cancer 
(Badawi, 1996). The mutations were not 
detected in two previous studies (Fugita et 
al, 1987; Ramchurren N et al, 1995). These 
findings indicate that the advanced stage of 
schistosomiasis-associated bladder cancer 
may not involve a high frequency of 
detectable mutations within the RAS genes. 
It is known that more than 90% of the SCC 
in the schistosome-infected bladder were 
advanced (stages T3 and T4) at the time of 
diagnosis. However, this does not exclude 
the possibility that activation in RAS could 
be an important factor in the initiation as 
well as promotion and progression of 
schistosomiasis-associated bladder cancer 
(Badawi, 1996). 
 
Further studies are needed to address the 
functional effect of KRAS mutations and the 
clinical relevance of these mutations in 
schistosomiasis-associated bladder cancer. 
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